Evidence map›Paper›PMID 38549814›Full record

ReviewAllergologie select2024

Monitoring mepolizumab treatment in chronic rhinosinusitis with nasal polyps (CRSwNP): Discontinue, change, continue therapy?

Ludger Klimek, Ulrike Förster-Ruhrmann, Heidi Olze, Achim G Beule, Adam M Chaker, Jan Hagemann, Tilman Huppertz, Thomas K Hoffmann, Stefan Dazert, Thomas Deitmer and 26 more

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Allergologie select, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Multi-omics integration andFrontiers in immunology · 2026
    Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors at 1 institution in 1 country.

Ludger KlimekCenter for Rhinology and Allergology, Wiesbaden.
Ulrike Förster-RuhrmannHNO-University Clinic Charité, Berlin.
Heidi OlzeHNO-University Clinic Charité, Berlin.
Achim G BeuleClinic for Otorhinolaryngology, Münster University Hospital.
Adam M ChakerDepartment of Otolaryngology - Head and Neck Surgery, Klinikum rechts der Isar, Technical University of Munich, Munich.
Jan HagemannClinic and Polyclinic for Otolaryngology, University Medical Center Mainz, Mainz.
Tilman HuppertzClinic and Polyclinic for Otolaryngology, University Medical Center Mainz, Mainz.
Thomas K HoffmannDepartment of Otorhinolaryngology, Head and Neck Surgery, University of Ulm, Ulm.
Stefan DazertClinic for Otorhinolaryngology, Head and Neck Surgery, Ruhr University Bochum, St. Elisabeth Hospital.
Thomas DeitmerGerman Society for Otorhinolaryngology, Head and Neck Surgery, Bonn.
Sebastian StriethClinic and Polyclinic for Otorhinolaryngology, University Hospital Bonn.
Holger WredeEar, nose and throat specialist, Herford.
Wolfgang W SchlenterMedical Association of German Allergists, Wiesbaden.
Hans-Jürgen WelkoborskyClinic for Ear, Nose and Throat Medicine, Head and Neck Surgery, Nordstadt Clinic of the KRH, Hannover.
Barbara WollenbergDepartment of Otolaryngology - Head and Neck Surgery, Klinikum rechts der Isar, Technical University of Munich, Munich.
Sven BeckerHNO-University Clinic Tübingen.
Fredericke BärholdHNO-University Clinic Tübingen.
Felix KlimekCenter for Rhinology and Allergology, Wiesbaden.
Ingrid CasperCenter for Rhinology and Allergology, Wiesbaden.
Jaron ZuberbierHNO-University Clinic Charité, Berlin.
Claudia RudackClinic for Otorhinolaryngology, Münster University Hospital.
Mandy CuevasClinic and Polyclinic for Otolaryngology, University Hospital Carl Gustav Carus, TU Dresden, Dresden.
Constantin A HintschichClinic and Polyclinic for Ear, Nose and Throat Medicine, University Hospital Regensburg, Regensburg.
Orlando Guntinas-LichiusClinic for Otorhinolaryngology, Jena University Hospital.
Timo StöverOtorhinolaryngology University Clinic Frankfurt am Main.
Christoph BergmannHNO RKM740 Interdisciplinary Specialist Clinic, Düsseldorf, Germany.
Pascal WerminghausPraxis für Hals-, Nasen-, Ohrenheilkunde und Allergologie, Düsseldorf.
Oliver PfaarClinic for Ear, Nose and Throat Medicine, University Hospital Giessen and Marburg GmbH, Marburg site, Philipps University Marburg, Marburg.
Jan GosepathClinic for Otorhinolaryngology, HSK Wiesbaden.
Moritz GrögerClinic and Polyclinic for Otorhinolaryngology, University Hospital LMU Munich.
Caroline BeutnerDepartment of Dermatology, Venereology and Allergology, University Medical Center Göttingen, Germany Klinik für Dermatologie, Venerologie und Allergologie, Universitätsmedizin Göttingen.
Martin LaudienDepartment of Otorhinolaryngology, Head and Neck Surgery, Kiel University, University Medical Centre Schleswig-Holstein, Kiel.
Rainer K WeberClinic for Otorhinolaryngology, Karlsruhe Municipal Hospital.
Tanja HildebrandDepartment of Ear, Nose and Throat Medicine, Freiburg University Medical Center.
Anna S HoffmannClinic for Ear, Nose and Throat Medicine, University Medical Center Hamburg-Eppendorf.
Claus BachertUpper Airways Research Laboratory and Department of Oto-Rhino-Laryngology, Ghent University and Ghent, University Hospital, Ghent, Belgium.
Zentrum für Rhinologie und Allergologie · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic rhinosinusitis with nasal polyps (CRSwNP) is a multifactorial inflammatory disease of the mucous membranes of the nose and sinuses. Eosinophilic inflammation is described as a common endotype. The anti-IL-5 antibody mepolizumab was approved in November 2021 as an add-on therapy to intranasal glucocorticosteroids for the treatment of adults with severe chronic rhinosinusitis with nasal polyps when systemic glucocorticosteroids or surgery do not provide adequate disease control. While national and international recommendations exist for the use of mepolizumab in CRSwNP, it has not yet been adequately specified how this therapy should be monitored, what follow-up documentation is necessary, and when it should be discontinued if necessary. MATERIALS AND

methodsA literature search was performed to analyze previous data on the treatment of CRSwNP with mepolizumab and to determine the available evidence by searching Medline, Pubmed, the national and international trial and guideline registries, and the Cochrane Library. Human studies published in the period up to and including 10/2022 were considered.

resultsBased on the international literature and previous experience by an expert panel, recommendations for follow-up, adherence to therapy intervals, and possible therapy breaks as well as discontinuation of therapy when using mepolizumab for the indication CRSwNP in the German healthcare system are given on the basis of a documentation sheet.

conclusionUnderstanding the immunological basis of CRSwNP opens up new non-surgical therapeutic approaches with biologics for patients with severe, uncontrolled courses. Here, we provide recommendations for follow-up, adherence to therapy intervals, possible therapy pauses, or discontinuation of therapy when mepolizumab is used as add-on therapy with intranasal glucocorticosteroids to treat adult patients with severe CRSwNP that cannot be adequately controlled with systemic glucocorticosteroids and/or surgical intervention.

Indexed as

biologicalschronic rhinosinusitisCRSwNPeosinophilic inflammationmepolizumab

Identifiers

PMID38549814
PMCPMC10975744
OpenAlexW4393042823

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.